Opinion|Videos|May 9, 2025
Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
Author(s)Sharon Walmsley, CM, MD, FRCPC
A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based therapy in patients with HIV, showing noninferiority with over 90% of patients maintaining viral suppression without excess toxicity.
Advertisement
New Drug Combination - Doravirine and Islatravir
Key Themes:
- Novel Combination Therapy: A late-breaker study presented at the Conference on Retroviruses and Opportunistic Infections showed noninferiority of doravirine (nonnucleoside reverse transcriptase inhibitor [NNRTI]) plus islatravir (nucleoside reverse transcriptase translocation inhibitor [NRTTI]) compared with a standard bictegravir-based regimen.
- Patient Selection Criteria: The study enrolled patients suppressed for at least 3 months on bictegravir with T-cell counts greater than 50 and no prior virologic failure.
- Safety Monitoring: Special attention was given to effects on CD4 counts and lymphocytes, as earlier studies with islatravir showed potential toxicity.
- Hepatitis B Considerations: The new combination lacks anti–hepatitis B virus (HBV) activity, requiring HBV screening before switching.
Notable Insights From Dr Sharon Walmsley:
- The doravirine/islatravir combination maintained viral suppression in more than 90% of patients over 144 weeks.
- No cases of treatment resistance were observed in participants experiencing virologic failure.
- Unlike in earlier studies, no evidence of lymphopenia or CD4 cell count reduction was observed with the islatravir component.
Only 2% to 3% of patients discontinued due to adverse events, indicating good tolerability.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
3
Metabolic Issues More Common in Patients With HIV
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5